Ctdna clinical trials

Explore recruiting ctdna clinical trials.

Recruiting ctdna studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ctdna trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)

Belgium, France, Germany, Ireland, Italy, Greece +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Double-blind, Multicenter, Randomized study of Atezolizumab (anti-PD‑L1 antibody) versus Placebo as Adjuvant therapy in Patients with High-Risk Muscle-Invasive Bladder Cancer who are CTDNA positive following cystectomy

Germany, Greece, Ireland, Spain, Poland, Czechia +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) AIO-KRK-0217.

Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer

Netherlands, Belgium, Spain, Greece, Portugal, Romania +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS

Spain, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

SURVIVE HERoes – A randomized Secondary Adjuvant Treatment Intervention study comparing Trastuzumab-Deruxtecan to SOC therapy in eBC Patients with Molecular Relapse

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Ctdna trials by city

Ctdna in Toronto Ctdna in Vancouver Ctdna in Montreal Ctdna in Calgary Ctdna in Edmonton Ctdna in Ottawa Ctdna in Winnipeg Ctdna in Quebec City Ctdna in Hamilton Ctdna in Kitchener Ctdna in London Ctdna in Halifax Ctdna in New York Ctdna in Los Angeles Ctdna in Chicago Ctdna in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease